Pricing Log in Create free account
Friday 6 November 2026 Export BMY’s income statement to Excel — free account

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue
+6.93%
EPS
−2.02%
Free cash flow
−36.0%
Total debt
−12.5%

Quarter to September 2026, against a year earlier

62.12 1.01 −1.60%
Market cap
$129.0B
P/E
13.7×
Fwd P/E
11.9×
Dividend yield
4.06%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Bristol Myers Squibb Company (BMY) EV/EBITDA

Alert me on EV/EBITDA

As of 6 November 2026, Bristol Myers Squibb Company (BMY) trades at a EV/EBITDA of 11.1×. Over the past ten years it has ranged from 7.0× (February 2024) to 137× (March 2025); the current reading is higher than 33% of that period. That is below the Drug Manufacturers General industry median of 14.7× and above the Healthcare sector median of 8.5×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 10.8× (91.40%)
FY2024 126× 1,573.66%
FY2023 7.5× (26.59%)
FY2022 10.2× 15.68%
FY2021 8.8× (82.26%)
FY2020 49.8× 137.96%
FY2019 20.9× 65.75%
FY2018 12.6× (26.65%)
FY2017 17.2× 8.83%
FY2016 15.8× (66.83%)

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 11.2× 12.57%
Jun 2026 9.9× (16.94%)
Mar 2026 11.9× 10.55%
Dec 2025 10.8× 12.55%
43 more quarters

Against its own ten years

Low 7.0× High 137×
Ten-year median 15.1×
Current reading's percentile 33

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.0×
GSK GSK PLC Sponsored ADR compare 10.5×
PFE Pfizer Inc. compare 10.7×
BMY Bristol Myers Squibb Company 11.1×
SNY Sanofi compare 11.4×
AZN AstraZeneca PLC compare 14.7×
NVS Novartis AG compare 15.6×
AMGN Amgen Inc. compare 16.9×
GILD Gilead Sciences, Inc. compare 504×
Drug Manufacturers General industry median 14.7×
Healthcare sector median 8.5×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on BMY